These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 22773810)

  • 21. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of lung cancers harboring NRAS mutations.
    Ohashi K; Sequist LV; Arcila ME; Lovly CM; Chen X; Rudin CM; Moran T; Camidge DR; Vnencak-Jones CL; Berry L; Pan Y; Sasaki H; Engelman JA; Garon EB; Dubinett SM; Franklin WA; Riely GJ; Sos ML; Kris MG; Dias-Santagata D; Ladanyi M; Bunn PA; Pao W
    Clin Cancer Res; 2013 May; 19(9):2584-91. PubMed ID: 23515407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
    Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
    Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
    Vojnic M; Kubota D; Kurzatkowski C; Offin M; Suzawa K; Benayed R; Schoenfeld AJ; Plodkowski AJ; Poirier JT; Rudin CM; Kris MG; Rosen NX; Yu HA; Riely GJ; Arcila ME; Somwar R; Ladanyi M
    J Thorac Oncol; 2019 May; 14(5):802-815. PubMed ID: 30831205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
    Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
    Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
    J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
    Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
    Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inactivation of
    Georgiou A; Stewart A; Cunningham D; Banerji U; Whittaker SR
    Mol Cancer Res; 2020 Jun; 18(6):835-846. PubMed ID: 32098826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
    Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
    Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined BRAF, EGFR, and MEK Inhibition in Patients with
    Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
    Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients.
    Er TK; Chen CC; Bujanda L; Herreros-Villanueva M
    Biomed Res Int; 2014; 2014():591867. PubMed ID: 25032217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
    Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
    Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
    Vandal G; Geiling B; Dankort D
    PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An amino-terminal
    Tung JK; Neishaboori N; Haraldsdottir S; Suarez CJ
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32669268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.